May 2, 2024Open Access

Real-world clinical evaluation of natural and induced vasomotor symptoms in the USA and Europe

SKSheryl A. KingsbergUniversity Hospitals of Cleveland VBVictoria BanksAmgen (United States)CCCecilia CaetanoBayer (Switzerland)

Key Points

Key points are not available for this paper at this time.

Abstract

This study aimed to examine physicians' and patients' perceptions regarding symptom burden and impact in women experiencing natural vasomotor symptoms (nVMS) or vasomotor symptoms induced by endocrine therapy for breast cancer (iVMS).

Perguntar à IA

Bookmark

View Full Paper

Cite This Study

Kingsberg et al. (Thu,) studied this question.

synapsesocial.com/papers/68e6bbe0b6db64358763ca86 https://doi.org/https://doi.org/10.1080/13697137.2024.2340472

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Current and future burden of breast cancer: Global statistics for 2020 and 20402022 · 3,259 citations
2Beyond frequency2008 · 166 citations
3Correction to: Qualitative study: burden of menopause-associated vasomotor symptoms (VMS) and validation of PROMIS sleep disturbance and sleep-related impairment measures for assessment of VMS impact on sleep2021 · 6 citations
4Value Cocreation in Health Care: Systematic Review2022 · 56 citations
5Early Discontinuation of Endocrine Therapy and Recurrence of Breast Cancer among Premenopausal Women2021 · 51 citations

Perguntar à IA

Bookmark

View Full Paper